Any prior treatment for the current breast cancer, including chemotherapy, hormonal therapy, radiation or experimental therapy
Other active malignancy requiring therapy such as radiation, chemotherapy, or immunotherapy.
Require concomitant chemotherapy, radiation therapy, or immunotherapy. Hydroxyurea is allowed up to the evening before starting (but not within  hours) of starting Induction therapy.
Treatment including radiation therapy, chemotherapy, or targeted therapy, for the currently diagnosed breast cancer prior to randomization.
Pre-planned concurrent cytotoxic chemotherapy, surgery, or radiation therapy during protocol treatment; radiation therapy is not permitted while on study
Not recovered from radiation and chemotherapy-induced AEs
Concomitant chemotherapy, radiation therapy, or immunotherapy
Treatment includes localized radiation therapy with or without chemotherapy
Recent chemotherapy or radiation therapy (within  days before first dose of lenzilumab)
Prior systemic chemotherapy or radiation therapy for transitional cell carcinoma of the bladder\r\n* Subjects who have received prior intravesical chemotherapy are allowed
No prior radiation therapy or chemotherapy within  month of study enrollment
Prior radiation therapy and/or chemotherapy, including cyclophosphamide, are permitted
Patients should have discontinued all previous intensive therapy, chemotherapy or radiotherapy for  weeks prior to commencing therapy on this study\r\n* NOTE: low dose chemotherapy or maintenance chemotherapy given within  days of planned study enrollment is permitted; these include hydroxyurea, -meraptopurine, oral methotrexate, vincristine, oral etoposide, and tyrosine kinase inhibitors (TKIs); FLT- inhibitors can also be given up to  days before conditioning regimen\r\n* All patients with prior radiation treatment to the lung, liver, and kidney will be excluded; for other scenarios of prior radiation treatment, up to  centigray (cGY) at  gray (Gy) per day will be allowed; inclusion of patients with previous radiation exposure will be determined based on the radiation oncologist medical doctor (MD) evaluation and judgment
Patients must have no had adjuvant therapy for the management of endometrial carcinoma; this includes chemotherapy, chemotherapy and radiation therapy, and/or consolidation/maintenance therapy; chemotherapy administered in conjunction with primary radiation as a radio-sensitizer WILL be counted as a systemic chemotherapy regimen; this also pertains to hormonal, vascular, and targeted therapy for the management of endometrial cancer
Finished their active cancer treatment (surgery, chemotherapy [chemo] and or radiation) at least  months prior to registration; (anti hormonal therapy will not prevent patient from participation as long as he/she can perform mild to moderate physical activities)
Patient who underwent chemotherapy, radiation therapy within  days before the screening period
Patients with prior chemotherapy or radiation therapy for their diagnosis of esophageal or gastric cancer. Patients with prior radiation therapy to same site for another diagnosis of cancer. Note: Patients may receive palliative radiation to their symptomatic sites of metastases but not definitive local therapy to esophageal or gastric primary prior to randomization. All patients may be enrolled on protocol then start systemic therapy; if they do not have evidence of disease progression at re-staging following initial therapy, they may be randomized
Treatment plan for bladder must include at least  weeks of daily radiation treatment (most patients will receive chemotherapy concurrent with radiation, but this is not required for trial enrollment)
Treatment with any chemotherapy, radiation therapy, biologics for cancer, or investigational therapy within  days of first administration of study treatment
Ongoing radiation therapy, chemotherapy, or hormonal therapy. Point radiation to a site of bone pain will be allowed.
Currently receiving chemotherapy, radiation therapy, investigational immunotherapy, or investigational biotherapy for breast cancer
Patients must be planning to undergo standard radiation/chemotherapy
Prior chemotherapy including cetuximab or radiation therapy
At least  prior platinum-based chemotherapeutic regimen, but not more than  prior chemotherapeutic regimens, for management of endometrial carcinoma. Prior treatment may include chemotherapy, chemotherapy/radiation therapy, and/or consolidation/maintenance therapy. Chemotherapy administered in conjunction with primary radiation as a radio-sensitized therapy will be considered a systemic chemotherapy regimen.
No prior chemotherapy, radiation therapy, or breast resection within  months of study entry
Patients who have not previously undergone radiation therapy can have a history of treatment with either chemotherapy (for unresectable/borderline resectable disease) or any combination of surgery and chemotherapy (for resectable disease); patients with no history of prior radiation treatment will constitute Cohort B and will receive SBRT as . Gy x ; please note that patients must have received at least two cycles of chemotherapy (with selection of drugs at the discretion of the treating oncologist) before SBRT treatment on protocol
No prior systemic (chemotherapy or biologic/molecular targeted therapy) or radiation treatment for head and neck cancer\r\n* Patients may have received chemotherapy or radiation for a previous, curatively treated non-HNSCC malignancy, provided at least  years have elapsed\r\n* Patients must be untreated with radiation above the clavicles
Prior radiation therapy, immunotherapy, chemotherapy or other investigational therapy given for prostate cancer
Plan for chemotherapy or targeted therapies during whole brain radiation or within  week of completing radiation therapy
Active cancer that requires therapy in the form of chemotherapy or radiation
Any prior treatment with radiation therapy or chemotherapy for the currently diagnosed breast cancer prior to registration; endocrine therapy may be given but not within  days prior to study entry and must be stopped if the patient will be receiving chemotherapy until completion of chemotherapy; patients must discontinue any hormonal agents such as raloxifene, tamoxifen, or other selective estrogen receptor modulators prior to registration
Prior radiation therapy, chemotherapy or extirpative surgery for rectal cancer
Major surgery, chemotherapy, radiotherapy, or other anti-cancer therapy within  weeks before randomization; Note: no washout required for single dose Gamma Knife radiation
Patients will be excluded if there is a plan to administer non-protocol chemotherapy, radiation therapy, or immunotherapy during the study period
At least  weeks from prior chemotherapy or radiation therapy to time of start of treatment, except for hydroxyurea or corticosteroid therapy which may be continued through cycle 
Any prior treatment with radiation therapy, chemotherapy, biotherapy, or hormone therapy for the currently diagnosed breast cancer prior to study enrollment
Patients will be ineligible if chemotherapy was completed >=  year from the planned start date of radiation therapy or if the patient is referred for radiation therapy after a relapse following a regimen with chemotherapy alone
No prior chemotherapy, radiation therapy, or breast resection within  months of study entry
Active carcinoma requiring systemic chemotherapy or radiation therapy
PHASE I: Patients may have had treatment for any number of prior relapses; relapse is defined as progression following initial therapy (i.e. surgery and radiation +/- chemotherapy [chemo] if that was used as initial therapy)
Require concomitant chemotherapy, radiation therapy, or immunotherapy. Hydroxyurea is allowed up to the evening before starting (but not within  hours) of starting treatment on either arm.
Patients must not have had any radiation therapy or chemotherapy for medulloblastoma prior to study enrollment
Chemotherapy is allowed; if chemotherapy is indicated and brachytherapy boost is planned, it must be administered after the accelerated whole breast irradiation (AWBI) but should begin no earlier than  days following completion of radiation therapy; alternatively if chemotherapy is indicated and external beam boost is planned, the chemotherapy can be delivered first, followed by radiation therapy beginning - days after the last cycle of chemotherapy or the radiation therapy can be delivered first and the chemotherapy can be delivered no earlier than  days post radiation therapy
For patients treated with external beam boost, prior chemotherapy if administered less than  weeks from start of radiation therapy or chemotherapy <  weeks after finishing radiation therapy; for patients treated with brachytherapy intracavitary device, chemotherapy prior to start of radiation therapy (RT)
Subjects may have had prior focal or systemic radiation or chemotherapy; at least  days must have elapsed since radiation treatment and  days since prior chemotherapy
Has had prior chemotherapy, radiation therapy, or immunotherapy for the diagnosis of iBCL
Patients must not have received any other anti-cancer treatment (including surgery, radiation or systemic chemotherapy) since the base trial.
The patient should be off chemotherapy, biologic therapy and radiation for  days.
Patients receiving chemotherapy or radiation (i.e., to the targeted lesion (s)) within the last two weeks
Less than  weeks since prior chemotherapy, radiation therapy, or immunotherapy. However, hydroxyurea is permitted up to  hours before the study is initiated;
If they are undergoing or have undergone in the past  weeks ( days) any other therapy for their cancer, including radiation therapy and chemotherapy
Patients with a cancer diagnosis, receiving chemotherapy, radiation therapy or the combination
Subjects with not meeting the above criteria are still eligible provided the patient declines concurrent chemotherapy with radiation, after specific informed consent describing the known benefits of adding chemotherapy to the definitive bladder radiation regimen; the reason for declining must be documented
Recommendation for combined chemotherapy and radiation therapeutic treatment
Prior systemic chemotherapy, molecularly targeted therapy, or radiation therapy for the current OPSCC diagnosis
Prior surgery and chemotherapy allowed, no prior radiation to the target area (breast or chest and nodes); NOTE: Radiation should occur - weeks after last chemotherapy or surgery, whichever comes last
Prior treatment \r\n* Prior medical therapy is allowed but not required\r\n* No limit on number of prior therapies\r\n* No chemotherapy, other investigational agents within  days of study treatment\r\n* No other concurrent investigational agents or other meningioma-directed therapy (chemotherapy, radiation) while on study\r\n* For patients treated with external beam radiation, interstitial brachytherapy or radiosurgery, an interval >  weeks must have elapsed from completion of radiation therapy to registration\r\n* Steroid dosing stable for at least  days \r\n* Recovered to Common Terminology Criteria for Adverse Events (CTCAE) grade  or less toxicity from other agents with exception of alopecia and fatigue\r\n* No craniotomy within  days of registration
Any prior chemotherapy or radiation therapy for the current diagnosis
Patients must have had at least one prior chemotherapeutic regimen for management of endometrial carcinoma; initial treatment may include chemotherapy, chemotherapy and radiation therapy, or consolidation/maintenance therapy; chemotherapy administered in conjunction with primary radiation as a radio-sensitizer WILL be counted as a systemic chemotherapy regimen\r\n* Patients are allowed to receive, but not required to receive, up to a total of  lines of chemotherapy
No previous chemotherapy or radiation therapy
Any prior treatment for the current breast cancer, including chemotherapy, hormonal therapy, radiation or experimental therapy
No prior systemic (chemotherapy or biologic/molecular targeted therapy) or radiation treatment for head and neck cancer\r\n* Patients may have received chemotherapy or radiation for a previous, curatively treated non-HNSCC malignancy, provided at least  years have elapsed\r\n* Patients must be untreated with radiation above the clavicles
Patients must have had one prior chemotherapeutic regimen for management of endometrial carcinoma; initial treatment may include chemotherapy, chemotherapy and radiation therapy, or consolidation/maintenance therapy; chemotherapy administered in conjunction with primary radiation as a radio-sensitizer WILL be counted as a systemic chemotherapy regimen
No prior chemotherapy or radiation therapy for HGG or DIPG is permitted; prior chemotherapy or radiation therapy for treatment of other malignancies is permitted
Subjects must have recovered from the acute side effects of any prior surgery, chemotherapy, or radiation therapy; a minimum time period at least  months should have elapsed from prior radiation treatment until enrollment in the study
Patients who received prior radiation therapy (RT) for treatment of germ cell tumor are eligible for this study as long as there is evidence of progressive disease determined by tumor markers or other sites of metastases outside of the radiated site; radiation must be completed prior to starting chemotherapy with the exception of brain metastases where chemotherapy and radiation can be given concurrently; toxicity from radiation must have recovered to grade  or less prior to initiating chemotherapy
PRIOR/CONCURRENT THERAPY CRITERIA: Patients must have documented progressive cancer following at least one but no more than two prior regimens of systemic therapy for lung cancer, one of which must have been platinum based combination chemotherapy; treatment with an immune therapy or targeted therapy for advanced disease will be considered a separate regimen and will count toward the prior regimens; maintenance therapy will not be counted as a separate regimen; adjuvant chemotherapy or chemotherapy administered as part of concurrent chemotherapy and radiation therapy for the treatment of lung cancer will not count as a prior regimen of systemic therapy as long as recurrence of patients lung cancer occurred more than  months after the last day of chemotherapy
Currently receiving chemotherapy, radiation therapy, immunotherapy, or biotherapy for breast cancer
Any prior treatment for the current breast cancer, including chemotherapy, hormonal therapy, radiation or experimental therapy
Patients must NOT have received prior chemotherapy or targeted therapy, including chemotherapy used for radiation sensitization for treatment of endometrial carcinoma
Prior surgery, radiation therapy, or chemotherapy other than biopsy or emergency procedure required for supportive care of this oral cavity cancer.
Prior chemotherapy or radiation therapy for any cancer
No treatment for current primary invasive adenocarcinoma of the breast such as irradiation, chemotherapy, immunotherapy, investigational therapy or surgery; previous treatment for breast and/or ovarian cancer with chemotherapy, endocrine therapy, surgery and radiation are allowed if >=  years prior to current diagnosis and there is no clinical evidence of metastatic disease
Prior non-hormonal therapy for the present breast cancer, including radiation therapy or chemotherapy
Any prior chemotherapy, targeted/biologic therapy, or radiation for treatment of the participants gastric or GE junction cancer
Receiving concomitant chemotherapy, radiation therapy, or immunotherapy during the duration of treatment on protocol, or within  days prior to enrollment
Participants who require active chemotherapy for another cancer; those requiring hormonal therapy or radiation therapy may be considered for enrollment on a case by case basis
In patients who have received prior radiation, at least  weeks should have elapsed since the completion of radiation therapy involving the whole pelvis or over % of the spine; if vaginal brachytherapy is planned with chemotherapy, it should be done before or after completion of chemotherapy treatment
Patients should have no contraindications for chemotherapy or radiation, and should receive either definitive chemoradiation therapy or preoperative chemoradiation therapy
Any previous systemic therapy (including chemotherapy, immunotherapy, HER targeted agents, and antitumor vaccines) for cancer, or radiation therapy for cancer
No prior chemotherapy, radiation, or biotherapy
PHASE I: Prior chemotherapy or radiation administered within  weeks from initiating study treatment
Any prior treatment with radiation therapy or chemotherapy for the currently diagnosed larynx cancer prior to registration
Patients must have had one prior chemotherapeutic regimen for management of cervical carcinoma; initial treatment may include chemotherapy, chemotherapy and radiation therapy, and/or chemotherapy as consolidation/maintenance therapy; chemotherapy administered in conjunction with primary radiation as a radiosensitizer will not be counted as a systemic chemotherapy regimen
Receiving concomitant chemotherapy, radiation therapy, or immunotherapy during the duration of treatment on protocol
Patients must complete the standard chemotherapy appropriate for the histologic subtype of lymphoma and be able to start radiation therapy within  months of completing chemotherapy
Endometrial cancer patients must be at least  months post-active chemotherapy and/or maintenance therapy treatment but not greater than  years post-active chemotherapy and/or maintenance therapy treatment; they must be at least  weeks post-radiation therapy (external beam radiation therapy [EBRT] or intravaginal radiation therapy [IVRT]) but not greater than  years post-radiation therapy
Prior chemotherapy or radiation therapy for any cancer
Intraventricular chemotherapy or radiation therapy within  days of starting treatment
Prior history of radiation or chemotherapy for MCL
Patients must have no prior chemotherapy or radiation therapy for lymphoma
Currently receiving any chemotherapy, investigational agents or registration on another therapy based trial or received chemotherapy with radiation therapy (e.g., temozolomide)
Patients will be ineligible if surgery and chemotherapy was completed >=  weeks from the planned start date of radiation therapy or if the patient is referred for radiation therapy after a relapse of prior ipsilateral breast cancer; surgery can exceed  weeks if the patient undergoes chemotherapy following surgery
Completed cancer specific therapy (including surgery, radiotherapy and/or chemotherapy) a minimum of  weeks prior to entry; (subjects with hormone receptor positive breast carcinoma maintained on hormonal therapy following chemotherapy and radiation are eligible)
Prior chemotherapy, radiation therapy, immunotherapy, or biotherapy for current breast cancer.
No prior radiation therapy or chemotherapy
Previous cytotoxic chemotherapy (e.g. alkylating chemotherapy, anthracyclines, and vinca alkaloids), radiation therapy, and any experimental therapy within the context of a clinical trial must have been discontinued at least  days prior to entry onto this study
Patients must have had one prior platinum-based chemotherapeutic regimen for management of endometrial carcinoma or carcinosarcoma; initial treatment may include chemotherapy, chemotherapy and radiation therapy, and/or consolidation/maintenance therapy; chemotherapy administered in conjunction with primary radiation as radio-sensitizer WILL be counted as a systemic chemotherapy regimen
No prior therapy for the tumor, including extensive surgery, radiation therapy, chemotherapy, immunotherapy, targeted therapy or any other investigational agents; surgical biopsy prior to beginning the study is allowable
Patients will be ineligible if chemotherapy was completed >=  year from the planned start date of radiation therapy or if the patient is referred for radiation therapy after a relapse following a regimen with chemotherapy alone
History of radiation or chemotherapy
Patients will be excluded if there is a plan to administer non-protocol chemotherapy, radiation therapy, or immunotherapy during the study period
Radiation/chemotherapy within  days
Patients will be excluded if there is a plan to administer non-protocol chemotherapy, radiation therapy, or immunotherapy during the study period.
Plan to administer non-protocol chemotherapy, radiation therapy, or immunotherapy during the study period.
Concurrent ongoing administration of systemic therapy (e.g. chemotherapy), or radiation therapy.
Major surgery, chemotherapy, radiation therapy or other cancer therapy within  weeks of treatment day 
Carcinoma requiring systemic chemotherapy or radiation therapy
Treatment with any chemotherapy, radiation therapy, biologics for cancer, or investigational therapy within  days of randomization
PRIOR THERAPY: Patients should have had NO prior chemotherapy agents for advanced or recurrent endometrial cancer; prior chemotherapy administration in conjunction with primary radiation therapy as a radiosensitizer would NOT exclude a patient from participation in this trial
Has had prior chemotherapy or radiation.
Patients must have had at least one but no more than four prior chemotherapeutic regimens for management of endometrial carcinoma (including neo-adjuvant and/or adjuvant chemotherapy); initial treatment may include chemotherapy, chemotherapy and radiation therapy, and/or consolidation/maintenance therapy; chemotherapy administered in conjunction with primary radiation as a radio-sensitizer WILL be counted as a systemic chemotherapy regimen
Prior treatment including surgery, chemotherapy or radiation therapy for the current primary breast cancer
Prior chemotherapy or radiation (within  days prior to the procedure or the duration of the subject's enrollment);
At least  days since chemotherapy or radiation
Received treatment with any systemic chemotherapy, experimental agent, or radiation therapy (with the exception of palliative localized radiation therapy) following completion of treatment on the ONT-- study
No prior chemotherapy, hormonal therapy, or radiation therapy for this cancer
Subjects who have received anti-cancer therapies within  weeks of the start of study drug (including chemotherapy, radiation therapy, immunotherapy, etc.).
Patient who have received chemotherapy, immunomodulatory drugs (e.g., lenalidomide, thalidomide or pomalidomide), immunotherapy, radiation therapy, or any investigational drug(s) within  days before enrollment or who have not recovered from the side effects of the therapy to at least grade ; localized radiation therapy to a single site within  days is acceptable
Patients with a prior history of chemotherapy, hormonal ablation therapy and/or radiation therapy.
Patients that have undergone PDT, chemotherapy or radiation therapy within the past  months will not be considered for enrollment
No prior medical therapy (chemotherapy, immunotherapy, biologic or targeted therapy) or radiation therapy for MM, unless locoregionally recurrent; if recurrent, no prior medical or radiation therapy is allowed for the latest recurrence
No prior systemic therapy for advanced NSCLC, including chemotherapy, targeted therapy or immunotherapy; prior palliative radiation permitted; prior adjuvant chemotherapy/radiation is permitted
Past history of prostate cancer or non-Hodgkins lymphoma with only active surveillance (i.e., no surgery, chemotherapy, or radiation therapy)
Undergoing treatment with surgery, chemotherapy, radiation, or combined modalities
Patients must be clinically stable and off treatment (e.g. radiation or chemotherapy) for >=  months
Have not completed surgery, chemotherapy, or radiation treatment associated with their diagnosis; a washout period of a minimum of  weeks is required from the last anti-cancer treatment received except hormonal therapy
Have had cancer treatment that included a surgical procedure, radiation therapy (RT), and/or chemotherapy (CTX)
Definitive radiation treatment with or without concurrent chemotherapy with curative intent; treatment prior to radiation therapy is acceptable (e.g. surgery, chemotherapy)
Undergoing radiation therapy or chemotherapy
Female breast cancer survivor who is over  month and less than  months beyond the completion of primary therapy (surgery, radiation, and chemotherapy).
Post active breast cancer therapy (e.g. surgery and/or chemotherapy and/or radiation therapy), but may still be undergoing maintenance cancer therapy and must be within  years of end of active treatment.
Chemotherapy or radiation therapy within the last  days
Are receiving active treatment (e.g., radiation, hormone, or chemotherapy) or have been receiving treatment in the past  months for prostate, breast, lung, lymphoma, or gynecological cancer
Diagnosis of a childhood cancer or similarly treated disease (involving chemotherapy, radiation, or surgery)
Ongoing chemotherapy, radiation therapy, or other cancer-related treatment
Patients who are receiving chemotherapy and radiation therapy
Undergoing chemotherapy or radiation therapy at any time during the study
Current chemotherapy or radiation therapy; participants in study may still be receiving hormone or Herceptin treatment
Completion of treatment (e.g., chemotherapy, radiation therapy, surgery, etc.) for gynecologic or breast cancer  months or greater in the past
Currently between . and . years from the completion of active cancer-directed therapy (cytotoxic chemotherapy, radiation therapy and/or definitive surgical intervention)
Currently undergoing chemotherapy treatment or within  weeks of end of chemotherapy (all participants must have had chemotherapy treatment)\r\n* Any radiation received must also be completed prior to randomization (if radiation treatment follows adjuvant chemotherapy, then the patient must be recruited within  weeks of end of radiation)\r\n* Maintenance hormonal therapy in women with breast cancer is allowed; see exclusion criteria regarding hormonal therapy in males with prostate cancer
Current systemic chemotherapy or radiation therapy that potentially causes bone marrow suppression that would preclude safe treatment of HSIL; Note: Kaposis sarcoma limited to the skin is not exclusionary unless requiring systemic chemotherapy
Undergoing chemotherapy or radiation
Receiving chemotherapy, biotherapy, or radiation therapy for cancer
Patients must have a history of stage , I, II or III colon or rectal adenocarcinoma that has been treated per standard care with resection alone or in combination with radiation or chemotherapy; adjuvant chemotherapy and radiation therapy (RT) treatment must have been completed at least  days prior to registration
Patients must not be expecting to receive radiation or additional chemotherapy
Participants must be at least  months from any prior cancer-directed treatment (such as surgical resection, chemotherapy, immunotherapy, hormonal therapy or radiation).
Completion of chemotherapy or trastuzumab for > six months and of radiation therapy for >=  months, as applicable and  years or less from completion of standard therapy
Ongoing chemotherapy, radiation therapy, or other cancer-related treatment
Have undergone treatment of hormone therapy, immunotherapy, chemotherapy and/or radiation for any malignancies within the past  years
Participants must be at least  months from any prior cancer-directed treatment (such as surgical resection, chemotherapy, immunotherapy, hormonal therapy or radiation)
Ongoing chemotherapy, radiation therapy, or other cancer-related treatment
Minimum -week interval from last chemotherapy administration and last breast surgery to radiation
Treatment including radiation therapy, chemotherapy, biotherapy, or hormonal therapy for this cancer prior to surgery (i.e., any neoadjuvant chemotherapy or endocrine therapy is not allowed); patients who undergo surgical resection with breast conservation and then are treated with adjuvant systemic therapy are eligible to enroll prior to the start of radiotherapy
No prior radiation therapy to the head and neck area, and no chemotherapy within the last year except for induction chemotherapy delivered (or to be delivered) prior to the current course of radiation therapy
Patients must have completed primary breast or ovarian cancer therapy (i.e., surgery, chemotherapy, immunotherapy and/or radiation therapy as appropriate per standard of care for patient's specific cancer)
Patients who will undergo standard radiation therapy with concurrent cisplatin-based chemotherapy for cervical cancer
Individuals can have a prior history of cancer; these individuals must be in stable remission and at least  months out from the completion of surgery/radiation therapy/chemotherapy; individual cases can be reviewed with the institutional principal investigator
Individuals can have a prior history of cancer; these individuals must be in stable remission and at least  months out from the completion of surgery/ radiation therapy/ chemotherapy; individual cases can be reviewed with the institutional principal investigator
Diagnosis of cervical cancer of any stage that will be treated with radiation therapy and concurrent chemotherapy
Anti-cancer treatment (chemotherapy and/or radiation therapy) within the last  weeks
No plans to undergo prostate cancer (PCa) therapy (with hormone therapy, chemotherapy, radium therapy, or external radiation) between the two study exams
Have undergone chemotherapy or radiation therapy within the previous one month
Subjects must not have been treated with chemotherapy or radiation for another malignancy within the preceding  months
Patients expected to be treated with radiation therapy, chemo-radiation therapy, or chemotherapy
Untreated low grade gliomas will be imaging-defined gliomas that have not yet been exposed to radiation or systemic chemotherapy; those exposed to therapy will have had radiation and/or systemic chemotherapy more than  month prior to scans
Have undergone chemotherapy or radiation therapy within the previous one month
Patients who are potential candidates to receive neoadjuvant therapy with either chemotherapy alone, radiation alone, immunotherapy alone, or combined treatment with any of these modalities; if on therapy, patients in whom a new treatment protocol or modality is being considered would be eligible
Previous treatment (chemotherapy, radiation, or surgery) to both breasts, including hormone therapy
No preoperative treatment for endometrial cancer including radiation or chemotherapy
The subject has had preoperative chemotherapy, immunotherapy, or radiation therapy within the  days prior to Lymphoseek administration
Prior receipt of any therapy, including local excision, radiation or chemotherapy, for the diagnosed rectal adenocarcinoma
There are no limits on prior therapy; patients are allowed to have prior chemotherapy, radiation therapy, and surgery; patients are allowed to have concurrent chemotherapy with radiation treatment; patients are allowed to have chemotherapy after radiation treatment; patients are not allowed to have planned lung resection after radiation
The patients must have no prior chemotherapy or radiation therapy as treatment
Undergone chemotherapy or radiation therapy in the past  months prior to enrollment
